{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:28:25Z","timestamp":1784341705701,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ijantimicag.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T13:48:22Z","timestamp":1498571302000},"page":"57-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin\u2013resistant Enterococcus spp (VRE): a single-center university hospital experience"],"prefix":"10.1016","volume":"51","author":[{"given":"Kairav J.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartikeya","family":"Cherabuddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Shultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Borgert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Ramphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P.","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/593956","article-title":"Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000\u20132006","volume":"30","author":"Ramsey","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2490-13-33","article-title":"Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series","volume":"13","author":"Ramaswamy","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijantimicag.2008.11.003","article-title":"Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections","volume":"33","author":"Fisher","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0030","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/jac\/dkw178","article-title":"Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis","volume":"71","author":"Seroy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrmicro2761","article-title":"The rise of the Enterococcus: beyond vancomycin resistance","volume":"10","author":"Arias","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0040","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1592\/phco.30.11.1136","article-title":"Vancomycin-resistant enterococcal urinary tract infections","volume":"30","author":"Heintz","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-196502000-00005","article-title":"Sodium ampicillin: absorption and excretion of intramuscular and intravenous doses in normal young men","volume":"249","author":"Eickhoff","year":"1965","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0050","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/AAC.35.11.2180","article-title":"Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution","volume":"35","author":"Grayson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0055","series-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2016"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jinf.2016.11.004","article-title":"Daptomycin non-susceptible Enterococcus faecium in leukemia patients: role of prior daptomycin exposure","volume":"74","author":"DiPippo","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","article-title":"Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005\u20132012)","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0070","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER Surveillance Program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0075","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1086\/523276","article-title":"Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus","volume":"28","author":"Pogue","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/659152","article-title":"Emergence of daptomycin-resistant VRE: experience of a single institution","volume":"32","author":"Kamboj","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0085","author":"US Department of Health and Human Services"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0095","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/427507","article-title":"Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults","volume":"40","author":"Nicolle","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1345\/aph.1A085","article-title":"In vitro assessment of urinary isolates of ampicillin-resistant enterococci","volume":"36","author":"Williamson","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0105","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1128\/AAC.01817-15","article-title":"Outcomes of aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections","volume":"59","author":"Cole","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0110","series-title":"Time to stop using alternatives to ampicillin for enterococcal UTIs? In-vitro susceptibility trends for enterococcus urinary isolates over a one-year period in Detroit","author":"Dumkow","year":"2013"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0115","first-page":"20","article-title":"Treatment of ampicillin-resistant enterococcus faecium urinary tract infections","volume":"32","author":"Richey","year":"2015","journal-title":"Federal Practitioner"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1469-0691.2007.01840.x","article-title":"Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci","volume":"14","author":"Sakka","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2047-2994-1-31","article-title":"Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study","volume":"1","author":"Karki","year":"2012","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0130","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/clinids\/20.5.1126","article-title":"Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection","volume":"20","author":"Edmond","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/501624","article-title":"Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality","volume":"20","author":"Lautenbach","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0140","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jac\/4.6.580","article-title":"Absence of bioactive metabolites of ampicillin and amoxycillin in man","volume":"4","author":"Cole","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.008_bib0145","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.00006-16","article-title":"Urinary tract infections: resistance is futile","volume":"60","author":"Wenzler","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T13:17:58Z","timestamp":1582550278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0924857917302182"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin\u2013resistant Enterococcus spp (VRE): a single-center university hospital experience","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}